Stifel analyst David Grossman lowered the firm’s price target on Health Catalyst (HCAT) to $3.75 from $4.50 and keeps a Hold rating on the shares after a “modest” Q3 revenue and EBITDA beat along with 2025 guidance being maintained. The absence of near-term catalysts is reflected in the multiple, but actions repositioning the business for growth and margin expansion create a potential opportunity for “those with longer-term perspective,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $5 from $6 at Wells Fargo
- Health Catalyst: Buy Rating Affirmed Amid Strong Financial Performance and Promising Future Prospects
- Health Catalyst price target lowered to $3.25 from $3.50 at Citi
- Health Catalyst Reports Strong Q3 2025 Performance
- Health Catalyst reports Q3 adjusted EPS 6c, consensus 7c